Serum HMGB1 Levels and Its Association With Endothelial Dysfunction in Patients With Polycystic Ovary Syndrome
| Autor: | Guang-da Xiang, Min Lin, Hao-Hua Wang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty Brachial Artery Endothelium Physiology chemical and pharmacologic phenomena 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Young Adult 03 medical and health sciences 0302 clinical medicine medicine.artery Internal medicine medicine TBARS Humans HMGB1 Protein Brachial artery Endothelial dysfunction Reactive hyperemia business.industry General Medicine medicine.disease Polycystic ovary Pathophysiology Metformin Vasodilation Endocrinology medicine.anatomical_structure Female Endothelium Vascular business Biomarkers Polycystic Ovary Syndrome medicine.drug |
| Zdroj: | Physiological Research. :911-919 |
| ISSN: | 1802-9973 0862-8408 |
| DOI: | 10.33549/physiolres.933831 |
| Popis: | High-mobility group box 1 (HMGB1) is newly discovered protein, which play a crucial role in the pathogenesis of systemic inflammation. Recent studies showed that HMGB1 is one of the important pathophysiological mechanisms in the occurrence and development of atherosclerosis. The purpose of the present study was to investigate the relationship between serum HMGB1 levels and endothelial function in patients with polycystic ovary syndrome (PCOS). Eighty newly diagnosed patients with PCOS and eighty normal women of similar age were selected. Metformin treatment (1,500 mg/day) was initiated in all patients for a period of consecutive 3 months. Serum HMGB1 levels were measured by ELISA. High resolution ultrasound was used to measure the brachial artery diameter at rest, after reactive hyperemia (flow-mediated arterial dilation, FMD) and after sublingual glyceryltrinitrate. Serum HMGB1 levels in PCOS were 24.87±14.93 ng/ml, which were significantly higher than that in controls (8.82±3.55 ng/ml, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|